Forns, Xavier <br/><br/>
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.  [electronic resource] 

 -  The Lancet. Infectious diseases  10 2017 
 - 1062-1068 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1474-4457 
<br/><br/><label>Standard No.: </label>10.1016/S1473-3099(17)30496-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Aminoisobutyric Acids<br/>Antiviral Agents--administration & dosage<br/>Benzimidazoles--administration & dosage<br/>Cyclopropanes<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepacivirus--classification<br/>Hepatitis C--drug therapy<br/>Humans<br/>Lactams, Macrocyclic<br/>Leucine--analogs & derivatives<br/>Liver Cirrhosis--complications<br/>Male<br/>Middle Aged<br/>Proline--analogs & derivatives<br/>Pyrrolidines<br/>Quinoxalines--administration & dosage<br/>Sulfonamides--administration & dosage